ARDX stock news

Biotech stocks rebounded in last week after declining modestly in the previous week. Some of the drugs that cleared the FDA hurdle this week include Ardelyx Inc (NASDAQ: ARDX )'s constipation drug Ibsrela; South African drugmaker Apsen Pharmacare's hydroxyprogesterone caproate, indicated to prevent preterm birth in pregnant women; and GlaxoSmithKline plc (NYSE: GSK )'s Nucala for treating severe eosinophilic asthma in children, ages 8-11 years. The week turned out to be a disappointing one for a few nano- and micro-cap stocks, which reported negative clinical trial readouts. Tocagen Inc (NASDAQ: TOCA ) tumbled about 78% after its brain cancer drug failed to ace a late-stage study and Ritter Pharmaceuticals Inc (NASDAQ: RTTR )'s pipeline asset to treat lactose intolerance also stumbled in a late-stage study, sending its shares to a record low. Here are the key catalysts a biotech investor needs to focus on for the upcoming week. Conferences Retina Society Annual Meeting 2019 Annual Meeting – Sept. 11-15, in London Global Summit On Cardiology & Heart Diseases – Sept. 16-17, in Dubai European Association for the Study of Diabetes, or EASD, 55th annual meeting – Sept. 16-20, in Barcelona, Spain 13th European Pediatric Neurology Society, or EPNS, Congress – Sept. 17 – 21, in Athens, Greece 4th Antibodies, Antibiotics and Bio … Read more
Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela. Read more
Ardelyx (ARDX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 11) Ardelyx Inc (NASDAQ: ARDX ) Avedro Inc (NASDAQ: AVDR ) Celgene Corporation (NASDAQ: CELG ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Enlivex Therapeutics Ltd (NASDAQ: ENLV ) The Medicines Company (NASDAQ: MDCO ) Medtronic PLC (NYSE: MDT ) Nevro Corp (NYSE: NVRO ) Radius Health Inc (NASDAQ: RDUS ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 11) CELYAD SA/ADR (NASDAQ: CYAD ) Endologix, Inc. (NASDAQ: ELGX ) Myovant Sciences Ltd (NYSE: MYOV ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) Karuna Therapeutics Inc (NASDAQ: KRTX ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP )(filed for a $12 million secondary offering) Tocagen Inc (NASDAQ: TOCA )( reported that its late-stage brain cancer study did not meet the primary endpoint) Trinity Biotech plc (NASDAQ: TRIB ) Stocks In Focus Ardelyx Gets FDA Nod For Constipation Drug Ardelyx announced the FDA has approved its tenapanor, brand name Ibsrela, a 50mg twice-daily oral pill for the treatment of irritable bowel syndrome with constipation in adults. Read more
FREMONT, Calif., Sept. 12, 2019 /PRNewswire/ -- Ardelyx, Inc. (ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that the U.S. Food and Drug Administration has approved IBSRELA Read more
Shares of the thinly traded, micro-cap biotech Ardelyx Inc (NASDAQ: ARDX ) have risen over 200% year-to-date. With a key binary event coming up, it's time for a look at what the future holds for the equity. The Company Ardelyx is a biopharma company developing drugs for cardiorenal diseases. The Fremont, California-based company was launched in 2007 and does not have a commercial product on the market. The company's revenues so far have mostly come from licensing. Ardelynx employs about 86 people, with roughly 70% of them being in R&D. The Pipeline The company's lead drug tenapanor, an NHE3 inhibitor, is being evaluated for multiple indications. 1. Tenapanor is being evaluated in a second Phase 3 trial dubbed "PHREEDOM" for the treatment of hyperphosphatemia, or elevated blood phosphate levels, in patients with end-stage renal disease, or ESRD, who are on dialysis. The pipeline asset is a novel, potent small-molecule dosed twice daily in milligram quantities. As opposed to current treatment options, which are mostly phosphate binders requiring multigram quantities, tenapanor is expected to significantly reduce patient pill burden. Read more
Ardelyx's (ARDX) lead pipeline candidate, tenapanor, meets primary endpoint in a pivotal phase III study. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 3) Ardelyx Inc (NASDAQ: ARDX ) ( reported positive results from a late-stage of its lead compound tenapanor in combination with phosphate binders to treat hyperphosphatemia in patients with chronic kidney disease on dialysis) China Biologic Products Holdings Inc (NASDAQ: CBPO ) DURECT Corporation (NASDAQ: DRRX ) Insulet Corporation (NASDAQ: PODD ) ( announced private offering of convertible senior notes) Lipocine Inc (NASDAQ: LPCN ) NextCure Inc (NASDAQ: NXTC ) The Medicines Company (NASDAQ: MDCO ) (announced positive Phase 3 results for inclisiran) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 3) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Aduro BioTech Inc (NASDAQ: ADRO ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Assembly Biosciences Inc (NASDAQ: ASMB ) BIOLINERX LTD/S ADR (NASDAQ: BLRX ) (announced completion of dose-escalation part of the Phase 1/2a study of AGI-134) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Gemphire Therapeutics Inc (NASDAQ: … Read more
Shares of Ardelyx Inc (NASDAQ: ARDX) were advancing strongly on above-average volume Tuesday following a clinical trial readout from the … Read more
Every investor in Ardelyx, Inc. (NASDAQ:ARDX) should be aware of the most powerful shareholder groups. Large companies… Read more
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
Mike Raab has been the CEO of Ardelyx, Inc. (NASDAQ:ARDX) since 2009. This analysis aims first to contrast CEO… Read more
Ardelyx (ARDX) delivered earnings and revenue surprises of -10.53% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock? Read more
In taking a look at some key indicators for Ardelyx, Inc. (NasdaqGM:ARDX), we note that the current Book to Market value for the firm is at 0.660735. The Book to Market or BTM is calculated as Market Read more
As Biotechnology businesses, ChromaDex Corporation (NASDAQ:CDXC) and Ardelyx Inc. (NASDAQ:ARDX), are affected by contrast. This especially applies to their dividends, analyst recommendations, profitab Read more

Proudly made at